Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business

Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies.  The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs.  SURESNES, France, July 13, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by...

Read more
Page 30 of 3370 1 29 30 31 3,370

Welcome Back!

Login to your account below

Retrieve your password

Please enter your username or email address to reset your password.